AUS
NZ
UK
CA
USA
IND
Imagion Biosystems Limited (ASX:IBX), a clinical-stage medical imaging firm advancing its proprietary MagSense4 cancer detection technology, has finalized the initial Tranche of a previously disclosed Placement, issuing 49,346,051 fully paid ordinary shares at $0.012 per share. On 2 July 2026, the company filed a Section 708A cleansing notice confirming that these shares were issued without a formal disclosure document under Part 6D.2 of the Corporations Act 2001. This cleansing notice permits the newly Issued Shares to be freely traded on the ASX, a necessary procedural step following placements conducted under the Corporations Act's disclosure exemptions. Investors focused on cancer diagnostics will be closely observing how Imagion utilizes the Capital raised through this placement to advance its MagSense4 platform targeting HER2-positive breast cancer, prostate cancer, and ovarian cancer applications.
Key Points
- Company: Imagion Biosystems Limited (ASX:IBX)
- Issued 49,346,051 fully paid ordinary shares at $0.012 (1.2 cents) per share as Tranche 1 of the placement announced on 25 June 2026
- Section 708A cleansing notice lodged on 2 July 2026, enabling the free trading of the newly issued shares
- Confirmed compliance with Chapter 2M, Section 674, and Section 674A of the Corporations Act as of the notice date
- No excluded information as defined by Sections 708A(7) and 708A(8) exists as of the notice date
- Investors should monitor for Tranche 2 of the placement and updates on the MagSense4 clinical development program
Imagion Issues 49.3 Million Shares at 1.2 Cents in Tranche 1 Placement
On 2 July 2026, Imagion Biosystems confirmed the issuance of 49,346,051 fully paid ordinary shares as part of the first tranche of a capital placement initially announced on 25 June 2026. Shares were priced at $0.012 each, totaling approximately $592,152 in gross proceeds. The company did not specify the overall capital raising target or detailed use of proceeds in this update.
The placement was executed without a formal product disclosure statement or prospectus under Part 6D.2 of the Corporations Act 2001, a common approach for ASX-listed companies issuing shares to sophisticated and professional investors under existing exemptions. The cleansing notice formalizes the regulatory process, confirming these shares are freely tradable and allowing investors to sell them on the ASX without standard disclosure obligations.
Significance of the Section 708A Cleansing Notice for Shareholders
The Section 708A cleansing notice, under the Corporations Act 2001, removes resale restrictions on shares issued without a disclosure document. Under Section 708A(5)(e), a company may issue this notice if it has met continuous disclosure requirements and no excluded information has been withheld under Sections 708A(7) and 708A(8).
Imagion Biosystems confirmed compliance with financial reporting obligations under Chapter 2M and continuous disclosure duties under Sections 674 and 674A as of the notice date. The company also affirmed that no excluded information exists. This confirmation is crucial for placement investors, providing the legal basis to freely trade or transfer their newly acquired shares on the ASX without further restrictions.
Overview of MagSense4 Technology and Targeted Cancer Indications
Imagion Biosystems is a clinical-stage medical imaging company focused on revolutionizing cancer diagnosis and treatment. Its flagship asset, MagSense4, is described as a first-of-its-kind MRI imaging agent enabling earlier and more precise cancer detection compared to traditional methods. The technology utilizes non-radioactive, bio-safe magnetic nanoparticles to enhance diagnostic certainty through molecular MRI.
The company’s development pipeline targets significant cancer indications including HER2-positive breast cancer, prostate cancer, and ovarian cancer. HER2-positive breast cancer is a critical market due to its prevalence and the importance of accurate HER2 status identification for treatment decisions. Should MagSense4 demonstrate clinical Utility in these areas, it could mark a substantial advance in non-invasive, non-radioactive cancer imaging. Investors should note that Imagion remains in the clinical stage, with its technology yet to receive regulatory approval and subject to clinical development risks.
Placement Announcement and Tranche Details
The placement, including Tranche 1, was first announced on 25 June 2026. Structuring capital raises in tranches is typical for ASX-listed small-cap and clinical-stage companies, balancing shareholder approval requirements and dilution management. Tranche 1 was issued under existing placement capacity without shareholder approval, while subsequent tranches may require shareholder meetings.
The company has not disclosed the size or timing of further tranches in this update. Investors tracking the full capital raising should refer to the original 25 June 2026 announcement or await further company updates regarding Tranche 2 and any associated shareholder approvals. A forthcoming general meeting may be necessary to approve additional share issuances beyond current placement capacity.
Compliance with Continuous Disclosure at Issuance
A valid Section 708A cleansing notice requires the company to affirm compliance with continuous disclosure obligations at the notice date. Imagion Biosystems stated it met the requirements of Sections 674 and 674A of the Corporations Act as of 2 July 2026, which mandate immediate disclosure of material information.
The company also confirmed no excluded information exists as contemplated by Sections 708A(7) and 708A(8). This legal affirmation is vital, as inaccuracies could invalidate the cleansing notice and restrict free trading of placed shares. The Board of Imagion Biosystems Limited authorized the notice, underscoring its collective endorsement of these statements.
Capital Position and Role of Equity Placements in Clinical-Stage Funding
ASX-listed clinical-stage medical technology and biotech companies typically rely on equity placements to finance research, development, and clinical trials, as they usually lack significant Operating Revenue. Imagion Biosystems fits this profile, advancing a novel medical imaging agent through clinical development. The placement announced on 25 June 2026 and partially completed via Tranche 1 aligns with expected capital raising activity at this stage.
The company did not disclose current cash reserves, cash Burn Rate, or detailed allocation of placement proceeds in this update. Investors seeking insight into funding runway should consult Imagion’s latest quarterly activities report or financial statements. The total capital to be raised through all tranches remains unconfirmed.
Board and Investor Relations Contacts
The cleansing notice was authorized by Imagion Biosystems Limited’s Board. Executive Chairman Bob Proulx can be reached via the Investor relations email at [email protected] or by phone at +61 3 9692 7222. For media and investor relations inquiries, Imagion engages Erich Boileau of Boileau & Co., contactable at [email protected] or by phone in the US at +1 (616) 786-4461.
Imagion also offers an Investor Hub at investor.imagionbiosystems.com, where shareholders and prospective investors may register for news updates and communicate with the company. This direct channel is particularly useful for retail shareholders wishing to stay informed about clinical progress and corporate developments.
Investor Considerations Moving Forward
The immediate market reaction to the completion of Tranche 1 was not evident from public data. Investors in clinical-stage companies like Imagion typically evaluate placements based on dilution impact, implied use of proceeds, and the company’s development timeline. The 1.2 cents per share placement price provides a benchmark for institutional and sophisticated investor valuation at the time.
Key upcoming milestones include announcements regarding Tranche 2, deployment of raised capital across the MagSense4 clinical program, and updates on clinical trials for HER2-positive breast cancer, prostate cancer, and ovarian cancer. Material developments could also arise from clinical results, regulatory interactions, or partnership/licensing activities. The company has not issued forward guidance in this update; investors should exercise caution given the risks inherent in clinical-stage medical technology development.
